Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder. The company is also developing TYRA-200, an FGFR1/2/3 inhibitor candidate for advanced or metastatic solid tumors with relevant FGFR alterations.

Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences conducts its research and clinical-development activities primarily in the United States, with clinical trials potentially involving sites in multiple countries. Todd Harris is the company’s co-founder and chief executive officer.

Key Stats

• Today's Range: $21.67 to $22.41
• 50-Day Range: $21.76 to $33.06
• 52-Week Range: $12.58 to $40.65
• Volume: 1.42 million shs
• Average Volume: 1.33 million shs
• Market Capitalization: $1.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.89
• Consensus Rating: Moderate Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 269th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tyra Biosciences has a consensus price target of $46.89, representing about 115.5% upside from its current price of $21.76.

Amount of Analyst Coverage

Tyra Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.68) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.92% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 5.68.

Change versus previous month

Short interest in Tyra Biosciences has recently increased by 4.63%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.75

News Sentiment

Tyra Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Tyra Biosciences this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for TYRA on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $20,004.00 in company stock, which represents 0.0015% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,004.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 87
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Tyra Biosciences: $46.89
• High Price Target: $56.00
• Low Price Target: $29.00
• Potential Upside/Downside: +115.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.39%
• Return on Assets: -43.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.90
• Quick Ratio: 14.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 4.48

Miscellaneous

• Outstanding Shares: 59,680,000
• Free Float: 52,217,000
• Market Cap: $1.30 billion
• Optionable: Optionable
• Beta: 0.73